Back to top

Analyst Blog

MannKind Corp. (MNKD - Analyst Report) recently announced that it satisfied the conditions for the second tranche of $40 million of 9.75% senior secured convertible notes under its finance agreement with Deerfield Management Company L.P. (Deerfield).

We note that in Jul 2013 the companies entered into a Facility Agreement, as per which MannKind has ensured financing worth $160 million from Deerfield. Deerfield has agreed to provide the loan through its purchase of four equal tranches of senior secured notes from MannKind. The notes, due to mature in 2019, will carry a yearly interest of 9.75%.

Deerfield paid the first of the four $40 million tranches following the closure of the deal. The next tranche was expected to be received following the achievement of results from MannKind’s phase III studies (Study 171 and Study175) on Afrezza. Afrezza, MannKind’s lead candidate, is being developed for the treatment of type I or type II diabetes. MannKind recently announced that both the studies met its primary objectives and Afrezza was well tolerated during the study. MannKind expects to receive the second tranche of $40 million by Sep 6, 2013.

The third tranche is expected to be on the repayment of its 3.75% Senior Convertible Notes due 2013. The final payment will be received on the approval of Afrezza by the U.S. Food and Drug Administration (FDA). MannKind further stated in its press release that a portion of the loan amount can be converted to shares of its common stock after a specified time following the publication of data from the Afrezza studies. As per the agreement, Deerfield received milestone rights from MannKind. Deerfield will receive up to $90 million on the achievement of some strategic and sales milestones.

Moreover, MannKind stated that less than 6 million shares will be issued on conversion if the conversion price is more than $6.67. Moreover, less than 12 million shares will be issued on conversion if the price is below $3.33. MannKind also mentioned that if the conversion price is between $3.33 and $6.67, not more than $40 million of common stock will be issued on conversion.

We are encouraged by MannKind’s efforts to raise funds. We expect the company to utilize the amount raised on Afrezza. The company is totally dependent on the success of the diabetes candidate.

Meanwhile, we expect investor focus to remain on Afrezza going forward. MannKind now plans to file the amended new drug application to the FDA for the candidate in early fourth quarter of 2013 based on positive results from phase III studies.

However, we remain concerned about the company’s over dependence on Afrezza. Any setback related to the diabetes candidate will be catastrophic for the company.

MannKind, a biopharma stock, presently carries a Zacks Rank #3 (Hold). Other biopharma stocks, such as Actelion Ltd. (ALIOF), Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) and Anthera Pharmaceuticals, Inc. (ANTH - Snapshot Report) are comparatively well placed. While Actelion carries a Zacks Rank #1 (Strong Buy), Alexion and Anthera carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 2.88 +3.22%
CENTURY ALU… CENX 22.22 +3.06%
ILLUMINA IN… ILMN 174.83 +2.55%
UNITED CONT… UAL 48.88 +2.52%
GTT COMMUNI… GTT 11.94 +2.49%